Managed Access Programs for AIN457, Secukinumab

Conditions

• Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• secukinumab — DRUG
  Patients receive secukinumab

Study Details

The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab

Key Dates

Status verified

Dec 2025

Central Contacts

• MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs
  1-888-669-6682
  [email protected]
• Novartis Pharmaceuticals
  +41613241111

Related Studies

• Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
  EARLY_PHASE1 · Recruiting · Virginia Clinical Research, Inc. · Norfolk, Virginia
• Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
  PHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
• Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
  PHASE2 · Recruiting · Zura Bio Inc · Phoenix, Arizona
• A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
  Recruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California